Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoradiotherapy plus TQB2450 for oligorecurrent/oligometastatic ESCC
ChiCTR2300072006Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of benmelstobart in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
benmelstobart
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300072006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072006.